WO2006029081A3 - Nucleoside-lipid conjugates, their method of preparation and uses thereof - Google Patents

Nucleoside-lipid conjugates, their method of preparation and uses thereof Download PDF

Info

Publication number
WO2006029081A3
WO2006029081A3 PCT/US2005/031543 US2005031543W WO2006029081A3 WO 2006029081 A3 WO2006029081 A3 WO 2006029081A3 US 2005031543 W US2005031543 W US 2005031543W WO 2006029081 A3 WO2006029081 A3 WO 2006029081A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
nucleoside
cardiolipin
analogues
lipid conjugates
Prior art date
Application number
PCT/US2005/031543
Other languages
French (fr)
Other versions
WO2006029081A2 (en
Inventor
Moghis U Ahmad
Shoukath M Ali
Abdul R Khan
Imran Ahmad
Original Assignee
Neopharm Inc
Moghis U Ahmad
Shoukath M Ali
Abdul R Khan
Imran Ahmad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Inc, Moghis U Ahmad, Shoukath M Ali, Abdul R Khan, Imran Ahmad filed Critical Neopharm Inc
Publication of WO2006029081A2 publication Critical patent/WO2006029081A2/en
Publication of WO2006029081A3 publication Critical patent/WO2006029081A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides methods for synthesizing nucleoside-lipid conjugates having varying fatty acid and alkyl chain lengths with or without unsaturation and their use in the treatment of cancer and viral diseases. More particularly, the invention provides methods for preparing gemcitabine-cardiolipin conjugates, and analogues thereof, cytarabine-cardiolipin conjugates, and analogues thereof. Additionally, the methods of the invention comprise administering a compound of invention as prodrug or a pharmaceutical preparation to combat mammalian diseases, preferably cancer, viral infections and bone disorders.
PCT/US2005/031543 2004-09-02 2005-09-02 Nucleoside-lipid conjugates, their method of preparation and uses thereof WO2006029081A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60661004P 2004-09-02 2004-09-02
US60/606,610 2004-09-02
US63232804P 2004-12-01 2004-12-01
US60/632,328 2004-12-01

Publications (2)

Publication Number Publication Date
WO2006029081A2 WO2006029081A2 (en) 2006-03-16
WO2006029081A3 true WO2006029081A3 (en) 2009-04-23

Family

ID=36036926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031543 WO2006029081A2 (en) 2004-09-02 2005-09-02 Nucleoside-lipid conjugates, their method of preparation and uses thereof

Country Status (1)

Country Link
WO (1) WO2006029081A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032897A1 (en) 2003-05-30 2022-07-27 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
PA8855701A1 (en) 2008-12-23 2010-07-27 NUCLEOSID ANALOGS
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2552931B1 (en) 2010-03-31 2014-07-23 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
JP6006292B2 (en) * 2011-04-08 2016-10-12 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for inhibiting influenza virus replication
WO2013043529A1 (en) * 2011-09-19 2013-03-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
JP6420247B2 (en) 2012-11-13 2018-11-07 ボーイエン セラピューティクス,インコーポレイティド Gemcitabine prodrug and use thereof
ES2771458T3 (en) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015030853A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
US10071112B2 (en) 2014-10-08 2018-09-11 Epigenetics Pharma Llc Vitamin E-nucleoside prodrugs
WO2021050629A1 (en) * 2019-09-10 2021-03-18 Virginia Commonwealth University Polymer drugs for cancer therapies
EP4248949A1 (en) 2022-03-21 2023-09-27 R.G.C.C. Holdings AG Liposomal compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3564089A (en) * 1966-09-29 1971-02-16 Sandra Jean Kiddy Diagnostic reagent for syphilis
US6384019B1 (en) * 1997-01-24 2002-05-07 Norsk Hydro Asa Gemcitabine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3564089A (en) * 1966-09-29 1971-02-16 Sandra Jean Kiddy Diagnostic reagent for syphilis
US6384019B1 (en) * 1997-01-24 2002-05-07 Norsk Hydro Asa Gemcitabine derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EARLY ET AL.: "Lake Michigan Sponge Phosphatic Metabolite Variations with Habitat: a 31P Nuclear Magnetic Resonance Study", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, PART B: BIOCHEMISTRY & MOLECULAR BIOLOGY, vol. 123B, no. 4, 1999, pages 329 - 343 *
HONG ET AL.: "Nucleoside Conjugates. 15. Synthesis and Biological Activity of Anti-HIV Nucleoside Conjugates of Ether and Thioether Phospholipidsl", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, 1996, pages 1771 - 1777 *
SCHNEIDER ET AL.: "Oligonucleotides containing flexible nucleoside analogs", JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 112, no. 1, 1990, pages 453 - 455 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV

Also Published As

Publication number Publication date
WO2006029081A2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
HK1102991A1 (en) Pharmaceutical formulation of decitabine
WO2006099169A3 (en) Novel liposome compositions
WO2005046575A3 (en) Amino acid prodrugs
WO2007062107A3 (en) Immunostimulatory oligoribonucleotides
WO2006063111A3 (en) Pharmaceutical formulations cytidine analogs and derivatives
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
WO2009019534A3 (en) Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
HK1116073A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
WO2006034154A3 (en) Salts of 5-azacytidine
WO2007054279A8 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2006037024A3 (en) Salts of decitabine
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
TW200626553A (en) Novel compounds
WO2008030818A3 (en) Novel liposome compositions
UA94036C2 (en) Bendamustine pharmaceutical compositions for lyophilisation
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
PL1727817T3 (en) Azabicyclooctan-3-one derivatives and use thereof
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
MX2020009150A (en) Cpg amphiphiles and uses thereof.
TW200745155A (en) Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid
WO2005092878A3 (en) Schweinfurthin analogues
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
WO2006032525A3 (en) Combinational therapy for treating cancer
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase